Sulphasalazine and Delagil--a comparative study in patients with juvenile chronic arthritis.
Thirty nine consecutive patients with pauciarticular and polyarticular juvenile chronic arthritis were randomised to treatment with either sulphasalazine or Delagil (chlorochinum diphosphoricum) in a parallel 6 month clinical trial. We compared clinical and laboratory signs of activity before and after the treatment. Of 21 patients with Sulphasalazine 10 were improved, 7 unchanged and in 4 patients had the therapy to be withdrawn. Of 18 patients with Delagil 5 were improved, 12 without effect and withdrawal was necessary in 1.
Hoza
J
J
IV. Department of Pediatrics, Charles University, Prague, Czechoslovakia.
Kadlecová
T
T
Nĕmcová
D
D
Havelka
S
S
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D002648:Child; D002738:Chloroquine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D012460:Sulfasalazine / Q000627:therapeutic use*
D000894:Anti-Inflammatory Agents, Non-Steroidal; D012460:Sulfasalazine; C023676:chloroquine diphosphate; D002738:Chloroquine